Treatment recommendations for chronic myeloid leukemia.
The first treatment of chronic myeloid leukemia (CML) included spleen x-radiation and conventional drugs, mainly Busulfan and Hydroxyurea. This therapy improved the quality of life during the chronic phase of the disease, without preventing nor significantly delaying the progression towards advanced phases. The introduction of allogeneic stem cell transplantation (alloSCT) marked the first important breakthrough in the evolution of CML treatment, because about 50% of the eligible patients were cured. The second breakthrough was the introduction of human recombinant interferon-alfa, able to achieve a complete cytogenetic remission in 15% to 30% of patients, with a significant survival advantage over conventional chemotherapy. At the end of the last century, about 15 years ago, all these treatments were quickly replaced by a class of small molecules targeting the tyrosine kinases (TK), which were able to induce a major molecular remission in most of the patients, without remarkable side effects, and a very prolonged life-span. The first approved TK inhibitor (TKI) was Imatinib Mesylate (Glivec or Gleevec, Novartis). Rapidly, other TKIs were developed tested and commercialized, namely Dasatinib (Sprycel, Bristol-Myers Squibb), Nilotinib (Tasigna, Novartis), Bosutinib (Busulif, Pfizer) and Ponatinib (Iclusig, Ariad). Not all these compounds are available worldwide; some of them are approved only for second line treatment, and the high prices are a problem that can limit their use. A frequent update of treatment recommendations is necessary. The current treatment goals include not only the prevention of the transformation to the advanced phases and the prolongation of survival, but also a length of survival and of a quality of life comparable to that of non-leukemic individuals. In some patient the next ambitious step is to move towards a treatment-free remission. The CML therapy, the role of alloSCT and the promising experimental strategies are reviewed in the context of the new therapeutic goals.
Department of Hematology and Oncology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy.
Michele
M
Baccarani
Institute of Hematology "L. and A. Seràgnoli", Department of Specialty, Diagnostic and Experimental Medicine, University of Bologna, S.Orsola-Malpighi University Hospital, Bologna, Italy.
Fausto
F
Castagnetti
Institute of Hematology "L. and A. Seràgnoli", Department of Specialty, Diagnostic and Experimental Medicine, University of Bologna, S.Orsola-Malpighi University Hospital, Bologna, Italy.
Gabriele
G
Gugliotta
Institute of Hematology "L. and A. Seràgnoli", Department of Specialty, Diagnostic and Experimental Medicine, University of Bologna, S.Orsola-Malpighi University Hospital, Bologna, Italy.
Francesca
F
Palandri
Institute of Hematology "L. and A. Seràgnoli", Department of Specialty, Diagnostic and Experimental Medicine, University of Bologna, S.Orsola-Malpighi University Hospital, Bologna, Italy.
Gianantonio
G
Rosti